1. Home
  2. SAFT vs REPL Comparison

SAFT vs REPL Comparison

Compare SAFT & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safety Insurance Group Inc.

SAFT

Safety Insurance Group Inc.

N/A

Current Price

$104.44

Market Cap

1.5B

Sector

Finance

ML Signal

N/A

Logo Replimune Group Inc.

REPL

Replimune Group Inc.

N/A

Current Price

$21.94

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SAFT
REPL
Founded
1979
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
SAFT
REPL
Price
$104.44
$21.94
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $23.33
AVG Volume (30 Days)
99.5K
★ 3.1M
Earning Date
11-04-2026
10-28-2026
Dividend Yield
★ 3.52%
N/A
EPS Growth
★ 40.17
N/A
EPS
★ 3.43
N/A
Revenue
★ $1,263,732,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$513.15
P/E Ratio
$30.46
★ N/A
Revenue Growth
★ 12.83
N/A
52 Week Low
$67.93
$1.50
52 Week High
$104.54
$23.41

Technical Indicators

Market Signals
Indicator
SAFT
REPL
Relative Strength Index (RSI) 64.58 73.83
Support Level $103.84 $7.11
Resistance Level N/A N/A
Average True Range (ATR) 0.22 1.56
MACD -0.01 0.74
Stochastic Oscillator 83.59 86.97

Price Performance

Historical Comparison
SAFT
REPL

About SAFT Safety Insurance Group Inc.

Safety Insurance Group Inc is a provider of private passenger automobile, commercial automobile, and homeowners insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. The company operates in the business segment of Property and casualty insurance operations.

About REPL Replimune Group Inc.

Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Share on Social Networks: